Take the SSRI Awareness Assessment Start Now
The Health Files
Investigating What America's Healthcare System Won't Tell You
Special Investigation

Your Doctor Never Told You What SSRIs Actually Do to Your Brain

SSRIs are one of the most harmful medications on the planet. And while some people do find short-term relief from sometimes crippling anxiety and poor mental health, the consequences are extreme. Forty million Americans are on these drugs right now. The overwhelming majority were never warned about brain remodeling, emotional blunting, or what happens when they try to stop.

By Mark Pescetti · Health Investigator · The Health Files · 16 min read

01 The Informed Consent Failure

The Conversation That Almost Never Happens

When a doctor hands a patient a prescription for sertraline, escitalopram, or fluoxetine, the conversation usually lasts about ninety seconds. You might hear the word "serotonin." You'll probably hear that it takes a few weeks to kick in. You'll be told about possible nausea or headaches in the beginning.

What you almost certainly will not hear is this: the drug you're about to take will physically restructure the way your brain processes emotions. That it will downregulate entire receptor systems. That between 40 and 60 percent of people who take it report feeling emotionally hollow.1 And that when you try to stop, your doctor will likely have no idea how to help you do it safely.

This isn't fringe science or anti-psychiatry conspiracy. Every claim in the paragraph above comes directly from peer-reviewed research published in journals like The Lancet Psychiatry, Frontiers in Psychiatry, and the British Journal of General Practice.2,3,4 The science has been available for years. The informed consent process has simply failed to catch up.

"Prescribers should ensure patients provide fully informed consent before starting antidepressants, explicitly discussing the risks of tolerance, dependence, and potentially severe, prolonged, or even irreversible withdrawal symptoms."
Therapeutics Letter 156, University of British Columbia (2025)

A 2023 study of 708 antidepressant users from 31 countries found a devastating pattern5: doctors were consistently ill-informed about withdrawal, frequently misdiagnosed withdrawal symptoms as relapse, and left patients to figure things out on their own through online support forums. Patients described prescribers who had no withdrawal plan, didn't believe their symptoms were real, and had no training in safe discontinuation.

In the United Kingdom, the Royal College of Psychiatrists issued a position statement acknowledging that antidepressant withdrawal effects are "more common, more severe, and more long-lasting than previously thought"6 and recommended that prescribers inform patients of these risks before initiating treatment. That was in 2019. Most prescribers still don't.

By The Numbers

The Scale of the Problem

40M+
Americans currently taking antidepressants
46%
of patients report emotional blunting on SSRIs/SNRIs
71%
of long-term users report feeling "emotionally numbed"
2-4 wk
standard taper guidelines recommend (shown to be inadequate)
DOSE vs. SEROTONIN TRANSPORTER OCCUPANCY Why linear dose reductions cause disproportionate withdrawal at low doses 0% 20% 40% 60% 80% Serotonin Transporter Occupancy 0 mg 5 mg 10 mg 20 mg 40 mg SSRI Dose (citalopram equivalent) DANGER ZONE Steepest receptor change Small dose drops at low doses = HUGE changes in brain chemistry Based on PET imaging data, Horowitz & Taylor, Lancet Psychiatry (2019)

The hyperbolic relationship between SSRI dose and serotonin transporter occupancy explains why standard linear tapers cause severe withdrawal at low doses.

02 The Brain Remodeling

Your Brain on SSRIs: Adaptation, Not Just Treatment

Here's what the 90-second prescription conversation leaves out entirely: when you take an SSRI, your brain doesn't just passively receive more serotonin and feel better. Your brain actively rewires itself in response to the drug. The medical term is neuroadaptation, and it changes the physical structure of how your neurons communicate.

SSRIs block the serotonin transporter, which causes serotonin to build up in the spaces between neurons. That part gets explained. What doesn't get explained is what happens next. Your brain recognizes the excess serotonin and begins compensating. It downregulates its serotonin receptors, which means it literally reduces the number of receptors available to receive the signal.7 The brain is trying to restore its original equilibrium, its homeostatic set-point, in the presence of a drug that's disrupting it.

This is why antidepressants take 2 to 4 weeks to produce a noticeable effect. The drug itself works within hours, blocking reuptake almost immediately. But the actual changes that produce the clinical effects are happening downstream: receptors are being dismantled, new receptor densities are being established, gene expression is being altered, and neurotrophic factors like BDNF are shifting the architecture of entire neural networks in the hippocampus and prefrontal cortex.8,9

This process is well documented. A 2021 review in Experimental and Therapeutic Medicine confirmed that antidepressants create structural changes in specific brain regions10, and that these changes are correlated directly with both symptom severity and the drug's therapeutic effects. Researchers at the University of Ottawa published work showing that serotonin receptors undergo extensive plasticity during SSRI use11, altering everything from synapse formation to glutamate receptor expression.

None of this is inherently evil. The brain's ability to adapt is remarkable. But this adaptation has a consequence that patients are almost never told about: once your brain has remodeled itself around the presence of the drug, removing the drug doesn't simply return you to where you started. Your brain has to remodel again, and that process takes far longer than 2 to 4 weeks.

How SSRIs Remodel Your Brain A three-phase process your doctor likely never explained PHASE 1 Hours to Days Drug blocks reuptake Pre-synaptic ↓ Serotonin floods gap Post-synaptic Normal receptor count Excess serotonin in gap No clinical effect yet PHASE 2 Weeks to Months Brain adapts & remodels Pre-synaptic ⚠ Receptors downregulate Post-synaptic Fewer receptors New homeostatic set-point Brain now depends on drug PHASE 3 Drug Removed Withdrawal begins Pre-synaptic ⚠ TOO FEW receptors for available serotonin Post-synaptic System in crisis Brain zaps, insomnia, panic Dizziness, rage, derealization Sources: PMC 3025168, Frontiers in Neuroscience (2019), Lancet Psychiatry (2019)
03 The Emotional Cost

Emotional Blunting: The Side Effect That Steals Your Life

Researchers at the University of Cambridge published a groundbreaking study that finally put clinical data behind something millions of SSRI users already knew: the drug that takes away the pain also takes away the joy. They called it emotional blunting, and it affects roughly half of everyone who takes these medications.12

Cambridge researchers administered escitalopram to healthy volunteers for at least 21 days and found something specific and measurable. The drug reduced sensitivity to reinforcement learning, which is how the brain recognizes and seeks out reward.12 When your reward circuitry gets dulled, pleasure doesn't register the way it should. Food tastes fine but doesn't satisfy. Music sounds normal but doesn't move you. A promotion at work produces a factual acknowledgment instead of genuine excitement. Your kid does something incredible and you know you should feel pride, but the feeling just isn't there.

The research from Oxford confirmed the prevalence. In one of the largest surveys of its kind, 46 percent of patients on SSRIs, SNRIs, or tricyclic antidepressants reported emotional blunting.13 A separate study found that 71 percent of long-term users reported feeling emotionally numb, 66 percent said they didn't feel like themselves, and 60 percent reported a reduction in positive feelings.14

And here's where the informed consent failure becomes almost unconscionable: emotional blunting was identified as one of the primary side effects driving patients to discontinue their medication against medical advice.1 People aren't non-compliant because they're irresponsible. They're stopping their drugs because the drugs are stripping away the emotional texture that makes life worth experiencing.

Patient Voices

The Comments Section Tells a Story Clinical Trials Don't

These are real comments from real people responding to conversations about SSRI prescribing. Every single one represents a patient whose doctor never had this conversation with them.

TikTok comments about SSRI experiences including a 17-year-old in protracted withdrawal after being prescribed at 14
Comments discussing being placed on psychiatric medications without understanding of long-term effects, and side effects of Seroquel at age 13
Comments about doctors dismissing requests to stop SSRIs, emotional blunting being horrific, and pharmaceutical industry practices
Comments about protracted withdrawal from Lexapro, Zoloft, and being tapered off too quickly losing jobs and relationships
Comments about 3 years in protracted hell after 26 years on SSRI, 2 years of akathisia, and 15 years on Lexapro with emotionless brain
Comments about Effexor brain zaps, 5 years in protracted withdrawal, panic from Prozac, and marriage and relationships destroyed by emotional blunting

Source: Public comments on social media discussing SSRI experiences. Names visible are public usernames on a public platform.

04 The Tapering Failure

Two to Four Weeks: The Guideline That Sets Patients Up to Fail

If the informed consent problem starts at prescription, it reaches its most dangerous point at discontinuation. The standard clinical guidelines for stopping an SSRI recommend a taper of 2 to 4 weeks, stepping down to therapeutic minimum doses or half-minimum doses before stopping completely. Dr. Mark Horowitz, a psychiatrist at University College London and the researcher who has done more than perhaps anyone else to expose this failure, has demonstrated exactly why this approach doesn't work.2

Studies comparing these standard short tapers to abrupt discontinuation found that the 2-to-4-week taper showed minimal benefit over just stopping cold.2 Patients suffered either way. In one observational study, 71 percent of respondents were unable to successfully discontinue their antidepressant using a standard linear taper.15 They experienced withdrawal symptoms so severe that they had no choice but to go back on the drug, often at a higher dose.

Why does this happen? It goes back to the brain remodeling. When a patient takes 20mg of an SSRI, the drug occupies roughly 80 percent of serotonin transporters. Dropping to 10mg sounds like cutting the dose in half, but it only reduces transporter occupancy by about 5 to 10 percentage points. The brain barely notices. But when you go from 5mg to 2.5mg, or from 2.5mg to zero, each reduction represents an enormous proportional change in what the brain is actually experiencing at the receptor level. This is where withdrawal hits hardest, and it's the exact point where the standard guidelines say to stop.

"It's as if there is some injury from coming off too quickly. The best approach is to prevent the problem, which is why I advocate for a long, hyperbolic taper. Otherwise, it's very difficult to put the toothpaste back in the tube."
Dr. Mark Horowitz, University College London

The withdrawal symptoms themselves are brutal and wide-ranging: brain zaps (electrical shock sensations in the head), insomnia, panic attacks that never existed before, akathisia (an internal restlessness so severe that patients describe it as torture), gastrointestinal chaos, flu-like symptoms, cognitive fog, depersonalization, and emotional instability. For some patients, these symptoms last not weeks but months. In some documented cases, years.

And here is the cruelest part: because many withdrawal symptoms overlap with the symptoms of depression and anxiety, doctors frequently misdiagnose withdrawal as relapse. The patient gets put back on the drug, often at a higher dose, and told they "need" to stay on it indefinitely. The research from the British Journal of General Practice confirmed this pattern explicitly: doctors failed to recognize withdrawal symptoms and diagnosed patients with relapse or new medical conditions, keeping people on medications they no longer needed.4

Linear vs. Hyperbolic

Two Ways to Stop an SSRI

Standard guidelines recommend a linear taper over weeks. The emerging science says that approach is fundamentally misaligned with how the brain actually responds to dose changes.

Standard Linear Taper

20mg → 10mg → 5mg → 0mg over 2-4 weeks. Equal dose reductions at each step.

Drops from 5mg to 0mg represent the largest proportional receptor change but get the same time as every other step.

71% of patients in one study couldn't complete this taper. Minimal benefit over stopping cold turkey.

Still recommended by most guidelines.

Hyperbolic Taper (Horowitz-Taylor)

20mg → 17.5mg → 15mg → 10mg → 7mg → 5mg → 3.5mg → 2.5mg → 1.5mg → 1mg → 0.5mg → 0.25mg → 0.1mg → 0mg over months to years.

Each step reduces serotonin transporter occupancy by the same percentage, giving the brain equal amounts of adjustment time at every phase.

Dramatically reduced withdrawal severity in observational studies of thousands of patients.

Published in The Lancet Psychiatry (2019).

First Person

I Lived Every Failure
This Article Describes

Mark Pescetti
Mark Pescetti
Health Investigator, The Health Files

I was prescribed citalopram for lupus. My doctor didn't explain what the drug would do to my brain, how long I might need to take it, or what would happen when I tried to stop. I was handed a prescription and told it would help. That was the entirety of my informed consent.

Over the years, I was pushed up to 40 milligrams, the maximum dose. I went on and off the drug multiple times with no guidance about what that kind of erratic dosing does to serotonin receptor systems. Nobody told me that each cycle of starting and stopping was training my nervous system into deeper dependency. Nobody told me that 40mg would reshape my receptor landscape at a level that takes years to undo.

Then the side effects started compounding. I developed severe emotional blunting, the exact phenomenon described in the research in this article. I lost the ability to feel genuine joy, genuine sadness, genuine anything. My libido vanished completely. I developed erectile dysfunction. The drug that was supposed to help me manage a chronic illness had quietly dismantled my ability to experience intimacy, connection, and the full range of human emotion. Nobody warned me that any of this was even a possibility.

When I finally decided the side effects were unbearable enough to try stopping, I did what my doctors told me to do. I tapered the standard way. I got down to 2.5 milligrams and stopped. The guideline-approved method. It caused a psychotic breakdown. Suicidal panic. Complete nervous system collapse.

I had to reinstate the drug and start the entire process over from scratch. This time, I switched to a compounded liquid formulation measured in 0.1 milliliter increments, because the standard pills that exist on pharmacy shelves don't allow the precision that safe tapering actually requires. I had to become my own pharmacologist. I had to learn about serotonin transporter occupancy curves, receptor downregulation, and hyperbolic dose reduction through my own research, because no doctor I saw had ever heard of any of it.

I got down to 1.7 milliliters and had to hold there for nearly two months while my brain stabilized. During that hold, I couldn't fall asleep before 1 in the morning. My blood pressure spiked. I lived in a state of constant sympathetic nervous system activation with almost no relief. I developed tinnitus that got louder as I lowered the dose, because the citalopram had been suppressing auditory nerve damage caused by Wellbutrin, another drug I'd been briefly prescribed with zero warning about permanent side effects. I experienced visual migraines triggered by screen exposure. Chest tightness. Heart rate spikes. Cognitive impairment so severe I couldn't hold a thought unless something externally triggered it.

All of this while managing an active lupus flare that had gone untreated, because no one connected the dots between the autoimmune disease and the psychiatric medication that was supposedly managing it.

I fought through it. I pushed down to sub-1 milliliter doses using liquid formulations and syringe measurements. Every fraction of a milliliter was its own battle. The emotional range is starting to come back. The sexual function is returning. I'm starting to feel like a human being again for the first time in years. But I had to survive a psychotic break, months of protracted withdrawal, and the complete absence of medical support to get here.

My doctor never told me about emotional blunting. Never told me about receptor downregulation. Never told me about protracted withdrawal. Never told me that a standard taper could cause psychosis. Never told me that hyperbolic tapering existed. Never told me that compounded liquid formulations were an option. I had to discover every single one of these things on my own, in crisis, while my nervous system was falling apart around me.

That's why I wrote this article. Every section of the research above maps directly onto what happened to me. This isn't academic. This isn't theoretical. This is what the informed consent failure looks like when it lands on a real person's life.

05 The Solution That Exists

Hyperbolic Tapering: What Your Brain Actually Needs

In 2019, Dr. Mark Horowitz and Dr. David Taylor published a landmark paper in The Lancet Psychiatry2 that should have changed prescribing practices overnight. They analyzed PET imaging data showing serotonin transporter occupancy at different SSRI doses and demonstrated something that, in retrospect, seems obvious: the relationship between dose and brain effect is not linear. It's hyperbolic.

What this means in plain language: the first few milligrams of an SSRI hit the brain hard. Going from 0mg to 5mg creates a massive change in serotonin transporter occupancy. Going from 15mg to 20mg barely changes it at all. The drug's relationship to the brain follows a steep curve that flattens out as doses increase.

This has profound implications for how you come off the drug. If you want the brain to experience each dose reduction as roughly the same amount of change (giving it the same amount of time to readjust at every step), you have to reduce the dose hyperbolically. Bigger reductions at the top, where each milligram matters less, and increasingly tiny reductions at the bottom, where each fraction of a milligram creates seismic shifts in receptor occupancy.

In practice, this means a patient coming off 20mg of citalopram might start by dropping to 17.5mg, then 15mg, then work down gradually over many months until they're measuring fractions of milligrams with liquid formulations or compounded capsules. A moderate taper might take a year. A cautious one might take two years. Reaching doses as low as 0.1mg before the final step to zero.

The observational data supports this approach. In a study of 608 patients in the Netherlands who used hyperbolic tapering strips providing daily micro-reductions, withdrawal was significantly more limited compared to standard approaches. Slower taper rates correlated directly with lower withdrawal severity.16

The Maudsley Deprescribing Guidelines, published by Horowitz and Taylor in 202417, now provide detailed hyperbolic tapering protocols for every major antidepressant. The information exists. The science is clear. The clinical infrastructure to support it is what's missing.

Tapering Protocol

What a Hyperbolic Taper Actually Looks Like

Based on the Horowitz-Taylor method from The Maudsley Deprescribing Guidelines. Each step reduces serotonin transporter occupancy by approximately the same amount.

Months 1-2
20mg → 15mg
Larger initial reductions. At these doses, each milligram removed has a relatively small impact on receptor occupancy. Can often use standard tablet splitting. Monitor every 2-4 weeks.
Months 3-5
15mg → 7mg
Reductions become smaller as each milligram now carries more proportional weight. May need to split tablets into quarters. If withdrawal symptoms appear, hold at current dose for 4-6 weeks before continuing.
Months 6-9
7mg → 2.5mg
This is where standard tapers end and hyperbolic tapering begins to diverge dramatically. Liquid formulations or compounding become necessary. Steps of 0.5-1mg. Each reduction waits for full stabilization before proceeding.
Months 10-14
2.5mg → 0.5mg
The danger zone. These low doses still occupy a significant percentage of serotonin transporters. Reductions of 0.25mg or smaller. Measured with 1mL syringes from liquid formulations. This is the phase where most standard tapers cause catastrophic withdrawal.
Months 14-18+
0.5mg → 0.1mg → 0mg
Final phase requires diluted solutions, often prepared by compounding pharmacies. Steps of 0.05-0.1mg. The brain needs maximum time at these doses to rebuild receptor density. The last step, from any dose to zero, deserves the longest hold.
DOSE STEPS VISUALIZED: SIZE OF EACH REDUCTION LINEAR 20→10mg 10→5mg 5→0mg ← EQUAL STEPS, UNEQUAL BRAIN IMPACT HYPER- BOLIC 20→10mg 10→5mg 5→2.5 2.5→1 1→.5 .5→.25 ← EQUAL BRAIN IMPACT PER STEP Adapted from Horowitz & Taylor, The Lancet Psychiatry (2019)
06 The Path Forward

What Informed Consent Should Actually Look Like

This is not an argument against antidepressants. SSRIs have helped some people, especially for the short term when mental health is in a dire state. The science of neuroplasticity that makes withdrawal difficult is the same science that allows these drugs to produce therapeutic effects in the first place. The brain's ability to remodel itself is remarkable. The question is whether patients deserve to understand what that remodeling actually entails before they agree to it.

But informed consent means patients deserve to know what they're signing up for before they sign up for it. It means a doctor should look a patient in the eye and say: this drug will change how your brain works at a structural level. It will take weeks to start working because your brain needs to adapt to it. When you want to stop, that adaptation means it may take months or years to come off safely. There is a roughly 50 percent chance you'll experience emotional blunting. The standard 2-to-4-week taper that most doctors follow has been shown to be inadequate for many patients. And if you experience severe withdrawal, there is currently a shortage of clinicians trained to help you.

That conversation takes five minutes. And it changes everything about how a patient approaches the decision to start, continue, or discontinue an SSRI.

The Therapeutics Initiative at the University of British Columbia published a recommendation in 202518 calling for formal documentation of informed consent before any antidepressant is prescribed, including explicit discussion of tolerance, dependence, and potentially severe withdrawal. The Royal College of Psychiatrists has taken a similar position.6 Dr. Horowitz's Maudsley Deprescribing Guidelines provide the clinical roadmap. The knowledge exists. The tools exist. What's missing is the will to change a prescribing culture that has spent decades treating these drugs as simple, safe, and easy to stop.

"We established a pattern of lack of information given to patients about the risk of antidepressant withdrawal. Doctors then failed to recognise the symptoms of withdrawal and were poorly informed about the best method of tapering."
British Journal of General Practice (2021)

Every patient taking an SSRI should know that hyperbolic tapering exists. Every patient should know that liquid formulations and compounding pharmacies can provide the micro-doses necessary for safe discontinuation. Every patient should know that withdrawal symptoms and relapse are clinically distinguishable, and that their doctor should know the difference. Every patient should know that communities of people who have navigated this successfully exist and can provide support when the medical system falls short.

The question is not whether these drugs should exist. The question is whether the people taking them deserve to make fully informed decisions about their own neurochemistry. The answer to that question is not complicated.

If you are currently taking an SSRI and considering changes to your medication, please work with a qualified healthcare provider. Do not alter your dose without medical guidance. If you are struggling with withdrawal or tapering, the Maudsley Deprescribing Guidelines and organizations like Surviving Antidepressants (survivingantidepressants.org) provide evidence-based resources and community support.

Important Disclaimer

This article is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. The information presented here is based on published, peer-reviewed research and publicly available clinical guidelines, but should not be used as a substitute for professional medical consultation.

If you are currently taking an SSRI or any psychiatric medication, do not alter your dosage or discontinue your medication without direct supervision from a qualified healthcare provider. Abrupt discontinuation of antidepressants can cause serious and potentially dangerous withdrawal effects.

If you are experiencing difficulties with your medication or are considering tapering, seek out a prescriber who is familiar with the Maudsley Deprescribing Guidelines or evidence-based hyperbolic tapering protocols. Organizations such as Surviving Antidepressants (survivingantidepressants.org) provide peer support and educational resources.

The Health Files is an independent educational platform. We are not affiliated with any pharmaceutical company, supplement brand, or medical practice. We receive no compensation from any entity referenced in this article. The views expressed reflect the current state of published research as of March 2026.

Individual responses to psychiatric medication vary widely. What is described in this article as a population-level trend may not reflect your personal experience. Your prescriber knows your specific medical history and is best positioned to guide your treatment decisions.

Bibliography

1. Ma, H., Cai, M. & Wang, H. (2021). "Emotional Blunting in Patients With Major Depressive Disorder: A Brief Non-systematic Review of Current Research." Frontiers in Psychiatry, 12, 792960. doi: 10.3389/fpsyt.2021.792960
2. Horowitz, M.A. & Taylor, D. (2019). "Tapering of SSRI treatment to mitigate withdrawal symptoms." The Lancet Psychiatry, 6(6), 538–546. doi: 10.1016/S2215-0366(19)30032-X
3. Sansone, R.A. & Sansone, L.A. (2010). "SSRI-Induced Indifference." Psychiatry (Edgmont), 7(10), 14–18. PMC2989833
4. Guy, A., Brown, M., Lewis, S. & Horowitz, M.A. (2021). "Four research papers I wish my GP had read before prescribing antidepressants." British Journal of General Practice, 71(708), 316–317. doi: 10.3399/bjgp21X716477
5. Davies, J., Pauli, R. & Montagu, L. (2023). "The need for antidepressant withdrawal support services: Recommendations from 708 patients." Psychiatry Research, 326, 115303. doi: 10.1016/j.psychres.2023.115303
6. Royal College of Psychiatrists (2019). Position Statement on Antidepressants and Depression. PS04/19. London: RCPsych.
7. Psychopharmacology Institute (2023). "Mechanism of Action of SSRIs." Review of 5-HT1A receptor downregulation and delayed therapeutic onset. psychopharmacologyinstitute.com
8. Andrade, C. (2011). "How antidepressant drugs act: A primer on neuroplasticity as the eventual mediator of antidepressant efficacy." Indian Journal of Psychiatry, 53(4), 378–386. doi: 10.4103/0019-5545.91914
9. Selective Serotonin Reuptake Inhibitor (overview). ScienceDirect Topics. Review of chronic SSRI effects on neurogenesis, BDNF expression, and synaptic remodeling. sciencedirect.com
10. Ménard, C., Bhatt, S. & Bhatt, D. (2021). "Neuroplasticity and depression: Rewiring the brain's networks through pharmacological therapy (Review)." Experimental and Therapeutic Medicine, 22(4), 1131. doi: 10.3892/etm.2021.10565
11. Albert, P.R. (2019). "Overcoming Resistance to Selective Serotonin Reuptake Inhibitors: Targeting Serotonin, Serotonin-1A Receptors and Adult Neuroplasticity." Frontiers in Neuroscience, 13, 404. doi: 10.3389/fnins.2019.00404
12. Langley, C., Armand, S., Luo, Q. et al. (2023). "Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study." Neuropsychopharmacology, 48, 664–670. doi: 10.1038/s41386-022-01523-x
13. Goodwin, G.M., Price, J., De Bodinat, C. & Laredo, J. (2017). "Emotional blunting with antidepressant treatments: A survey among depressed patients." Journal of Affective Disorders, 221, 31–35. doi: 10.1016/j.jad.2017.05.048
14. Read, J. & Williams, J. (2018). "Adverse Effects of Antidepressants Reported by a Large International Cohort: Emotional Blunting, Suicidality, and Withdrawal Effects." Current Drug Safety, 13(3), 176–186. doi: 10.2174/1574886313666180605095130
15. Davies, J. & Read, J. (2019). "A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based?" Addictive Behaviors, 97, 111–121. doi: 10.1016/j.addbeh.2018.08.027
16. Groot, P.C., Consenso de Vos, N., Becx, M. et al. (2023). "Outcomes of hyperbolic tapering of antidepressants." Therapeutic Advances in Psychopharmacology, 13. doi: 10.1177/20451253231171518
17. Horowitz, M. & Taylor, D.M. (2024). The Maudsley Deprescribing Guidelines: Antidepressants, Benzodiazepines, Gabapentinoids and Z-drugs. Chichester: John Wiley & Sons.
18. Therapeutics Initiative (2025). "Antidepressant withdrawal syndrome – Update." Therapeutics Letter 156. University of British Columbia. ti.ubc.ca
19. Branchi, I. (2011). "The double edged sword of neural plasticity: Increasing serotonin levels leads to both greater vulnerability to depression and improved capacity to recover." Psychoneuroendocrinology, 36(3), 339–351. doi: 10.1016/j.psyneuen.2010.08.011
20. Kraus, C., Castrén, E., Kasper, S. & Lanzenberger, R. (2017). "Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression." Neuroscience & Biobehavioral Reviews, 77, 317–326. doi: 10.1016/j.neubiorev.2017.03.007
21. Horowitz, M. & Wilcock, M. (2025). "Newer generation antidepressants and withdrawal effects: reconsidering the role of antidepressants and helping patients to stop." Drug and Therapeutics Bulletin. Cited in Medscape (Aug 2025).
22. Cartwright, C., Gibson, K., Read, J. et al. (2016). "Long-term antidepressant use: patient perspectives of benefits and adverse effects." Patient Preference and Adherence, 10, 1401–1407. doi: 10.2147/PPA.S110632
23. Fava, G.A., Gatti, A., Belaise, C. et al. (2015). "Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: A systematic review." Psychotherapy and Psychosomatics, 84(2), 72–81. doi: 10.1159/000370338
24. Rosenbaum, J.F., Fava, M., Hoog, S.L. et al. (1998). "Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial." Biological Psychiatry, 44(2), 77–87. doi: 10.1016/S0006-3223(98)00126-7
25. Baldisseri, M. (2021). "Informed Consent Must Reflect Information from Online Withdrawal Forums." Mad in America. Review of legal precedent and informed consent requirements for psychiatric medication. madinamerica.com